Search

ASH 2024: Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more
He discusses this year's Cartitude 4 approval, plus current studies in 1L multiple myeloma. Also, his take on a potential future...
Dec 9, 2024

Legend Biotech's CEO Ying Huang on moving CARVYKTI into earlier lines of treatment in the E.U. and U.S.
Ying Huang talks about Friday's CHMP positive opinion and the upcoming FDA advisory committee meeting, and highlight's Legend's pipeline.
Feb 26, 2024